December 22, 2025

Long-Term Tofersen Shows Benefit in SOD1-Mutated ALS

Final data from the phase III VALOR trial and its open-label extension study showed that patients with SOD1-mutated ALS benefit from treatment with the intrathecal antisense oligonucleotide tofersen.

Conexiant

December 18, 2025

Psychiatric Genetics: Shared Risk Across Disorders

Large-scale genomic analysis of 14 psychiatric disorders identified five underlying genetic factors and biological pathways

Conexiant

December 12, 2025

Autism's 3-Hit Model Targets Mitochondria

Three necessary metabolic disruptions converge on cell danger response, suggesting prevention opportunities.

Conexiant

December 12, 2025

Nine Breakthrough Studies Define 2025 Research

From GLP-1 cardioprotection to genome sequencing in newborns, this year's top research spans critical clinical frontiers.

Conexiant

December 10, 2025

HyperCKemia and Involuntary Movements: What’s Your Diagnosis?

Routine laboratory studies were within reference ranges except for striking hyperCKemia of 1961 U/L.

Conexiant

December 09, 2025

The $100K Rule No One Saw Coming

Rural hospitals warn that a sudden visa cost hike could deepen dire workforce gaps.

KFF Health News

December 08, 2025

The Case of the Hospital That Isn’t

A bureaucratic showdown over North Carolina’s certificate-of-need laws has stalled a critical hospital project, straining care in the state’s mountain communities.

Conexiant

December 05, 2025

On the Edge of a Measles Comeback?

New analysis examines rising U.S. measles outbreaks, associated clinical risks, and the potential loss of measles-elimination status.

KFF Health News

December 04, 2025

FDA Approves Biologic for Nerve Repair

A newly licensed biologic offers a novel approach to repairing complex peripheral nerve injuries across pediatric and adult populations.

Conexiant